Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
106-120 of 362

Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CENavigating Treatment Sequencing After Frontline Treatment Failure in CLL

Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CEProgress in Breast Cancer Care: Translating SABCS Data Into Practice

Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors

NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
- advertisement

Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations

Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer

Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting

RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing

Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
- advertisement

Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CEFrontline Insights: Emerging Therapeutic Strategies in HNSCC

Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
CME/CEBreaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma

Interdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care
CME/CE Broadcast ReplayInterdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care






































